Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/44 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.0930316Oral product for the prevention and treatment of infectious gastroenteritides in calves
EP 21.07.1999
Int.Class A61K 39/108
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
108Escherichia; Klebsiella
Appl.No 98310267 Applicant MEDIPHARM CZ S R O Inventor MICAN PETR
Oral product for the prevention and therapy of infectious gastroenteritis in calves that contents of antibodies to bovine rotavirus, bovine coronavirus and enterotoxigenic strains of Escherichia coli prepared from colostrum of immunized cows and/or egg yolks of immunized hens. It contents also a stabilized live culture of lactacidogenic bacteria. Method of production of antibodies to bovine rotavirus, bovine coronavirus and enterotoxigenic strains of Escherichia coli by immunization of cows and/or hens with antigens of bovine rotavirus, bovine coronavirus and enterotoxigenic strains of Escherichia coli, collection of colostrum from the immunized cows and/or egg yolks from the immunized hens and processing of these semi-products into the administration form, for instance by drying.
2.20080299138Toll-Like Receptor 3 Modulators and Uses Thereof
US 04.12.2008
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No 12126150 Applicant DUFFY KAREN E Inventor Duffy Karen E.

Modulators of TLR3 activity and their use are disclosed.

3.WO/2014/079000BISPECIFIC ANTIBODY
WO 30.05.2014
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/CN2012/084982 Applicant WUHAN YZY BIOPHARMA CO., LTD. Inventor ZHOU, Pengfei
Provided are bispecific antibodies comprised of a single-chain unit having specificity to an immune cell and a monovalent unit having specificity to a tumor cell or a microorganism. The single-chain unit includes a single-chain variable fragment (scFv) fused to an Fc fragment and the monovalent unit includes a light chain and heavy chain pair. Also provided are methods of preparing bispecific antibodies and pharmaceutical and diagnostic uses of these antibodies.
4.112062859Chimeric antigen receptor for pathogen clearance and application thereof
CN 11.12.2020
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No 202010908371.5 Applicant FENGCHAO PHARMACEUTICAL TECHNOLOGY (SHANGHAI) CO., LTD. Inventor HU SHI
The invention provides a chimeric antigen receptor (CAR) polypeptide for pathogens. The chimeric antigen receptor polypeptide is provided with: (a) an extracellular domain comprising one or more antigen binding regions having pathogen-related antigen specificity; (b) a transmembrane domain; and (c) one or more copies of an intracellular signal domain of a 'eat-me' signal receptor, which can be specifically bound to a pathogen antigen and activate an endogenous silence type phagocytic clearance signal. Further, the invention also provides polynucleotides encoding the polypeptide, gene vectors,recombinant cells carrying chimeric antigen receptors, and a composition. The chimeric antigen receptor characteristically mediates recombinant cells to perform phagocytic clearance on the pathogens,and does not significantly release cytokines, so that a 'silence' type pathogen clearing mode is actually realized.
5.WO/2020/023310COMPOSITIONS OF FCRN ANTIBODIES AND METHODS OF USE THEREOF
WO 30.01.2020
Int.Class A61K 31/7016
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7016Disaccharides, e.g. lactose, lactulose
Appl.No PCT/US2019/042597 Applicant MOMENTA PHARMACEUTICALS, INC. Inventor ZHANG, Zhongli
Stable pharmaceutical compositions containing an anti-FcRn antibody are described and characterized.
6.WO/2009/051265STABILISATION OF ANTIBODIES ON HAZARDOUS SUBTANCE-REMOVING MATERIAL AND METHOD OF REMOVING HAZARDOUS SUBSTANCES
WO 23.04.2009
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2008/069073 Applicant FUJIFILM CORPORATION Inventor IWANAGA, Hiroshi
A hazardous substance-removing material which comprises a support having antibodies supported thereon, in which at least one member selected from the group consisting of sugars, amino acids, SH group-protecting agents, and surfactants is incorporated as an antibody-stabilizing agent, in which the antibodies are highly stable, is provided.
7.20110274701COMPOSITION AND METHOD FOR PREVENTING/DECREASING RESPIRATORY ILLNESS
US 10.11.2011
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No 13103559 Applicant Camas Incorporated Inventor Mitteness Bradley M.

A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air. The adherence inhibiting material can be formulated for use in a variety of ways such as an oral spray or a nasal spray. These formulations can be effective to prevent or reduce respiratory illnesses in animals and humans.

8.20150175711Anti-CD22 anti-idiotypic antibodies and uses thereof
US 25.06.2015
Int.Class C07K 16/42
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
42against immunoglobulins (anti-idiotypic antibodies)
Appl.No 14407988 Applicant SINOMAB BIOSCIENCE LIMITED Inventor Shui-on Leung

The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (the anti-CD22 antibodies). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for the anti-CD22 antibodies. The present invention is directed against a method for identifying and evaluating the activities and concentration of the anti-CD22 antibodies. Additionally, the present invention provides a method for evaluating serum concentration of the anti-CD22 antibodies that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with the anti-CD22 antibodies. Specifically, the present invention is directed against the establishment of a cell line expressing surface concentration of the antibody of the invention; the said cell line expressing surface anti-idiotype antibodies or antibody fragments will be used as the target cell line for evaluating the functional activities of the anti-CD22 antibodies via complement dependent cytotoxicity (CDC) and/or antibody dependent cell cytotoxicity (ADCC) activities.

9.20160363597Cell lines expressing surface bound anti-idiotype antibodies against anti-CD22 antibodies and uses thereof
US 15.12.2016
Int.Class C12P 21/06
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21Preparation of peptides or proteins
06produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Appl.No 15186999 Applicant SINOMAB BIOSCIENCE LIMITED Inventor Shui-on Leung

The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (“the anti-CD22 antibodies”). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for “the anti-CD22 antibodies.” The present invention is directed against a method for identifying and evaluating the activities and concentration of “the anti-CD22 antibodies.” Additionally, the present invention provides a method for evaluating serum concentration of “the anti-CD22 antibodies” that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with “the anti-CD22 antibodies.” Specifically, the present invention is directed against the establishment of a cell line expressing surface concentration of the antibody of the invention; the said cell line expressing surface anti-idiotype antibodies or antibody fragments will be used as the target cell line for evaluating the functional activities of “the anti-CD22 antibodies” via complement dependent cytotoxicity (CDC) and/or antibody dependent cell cytotoxicity (ADCC) activities.

10.20140220133Nanotechnology Based Medicine for Biodefense
US 07.08.2014
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No 14092338 Applicant CytImmune Sciences, Inc. Inventor Paciotti Giulio F.

A composition and methods to bind and remove toxic agents from a subject exposed to the toxic agents are described herein. The composition comprises a stealth agent and scavenging agent bound to a nanoparticle platform. The stealth agent prevents the nanomedicine from detection and elimination by the immune system allowing the scavenging agent to bind the target toxic agent. The stealth agent comprises an exposing group that once removed from the stealth agent allows the nanomedicine and bound toxic agent to be detected and eliminated from the subject's body.